SpecificgyrAgene mutations predict poor treatment outcome in MDR-TB

Systematic Review of Mutations in Pyrazinamidase Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis Clinical Isolates

(2015) Sarah M. Ramirez-Busby et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mycobacterium tuberculosispncAPolymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT: TABLE 1

(2015) Michael G. Whitfield et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated with Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A Systematic Review

(2015) Elisea Avalos et al.   PLoS One

Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

(2014) K. J. M. Aung et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis

(2014) Corinne S. Merle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis

(2014) Jing Li et al.   Emerging Microbes & Infections

Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis

(2013) Zahoor Ahmad et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients

(2013) Mohideen S. Jawahar et al.   PLoS One

Extending the Definition of the GyrB Quinolone Resistance-Determining Region in Mycobacterium tuberculosis DNA Gyrase for Assessing Fluoroquinolone Resistance in M. tuberculosis

(2012) Alix Pantel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

(2012) Dennis Falzon et al.   EUROPEAN RESPIRATORY JOURNAL

Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin

(2012) E. Y. Nosova et al.   JOURNAL OF MEDICAL MICROBIOLOGY

New Insights into Fluoroquinolone Resistance in Mycobacterium tuberculosis: Functional Genetic Analysis of gyrA and gyrB Mutations

(2012) Seidu Malik et al.   PLoS One

Impact of the E540V Amino Acid Substitution in GyrB ofMycobacterium tuberculosison Quinolone Resistance

(2011) Hyun Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DNA Gyrase Inhibition Assays Are Necessary To Demonstrate Fluoroquinolone Resistance Secondary togyrBMutations in Mycobacterium tuberculosis

(2011) Alix Pantel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosisisolates from East China in 2009

(2011) Zhenling Cui et al.   BMC INFECTIOUS DISEASES

The ins and outs of Mycobacterium tuberculosis drug susceptibility testing

(2011) E.C. Böttger   CLINICAL MICROBIOLOGY AND INFECTION

High Proportion of Fluoroquinolone-Resistant Mycobacterium tuberculosis Isolates with Novel Gyrase Polymorphisms and a gyrA Region Associated with Fluoroquinolone Susceptibility

(2011) R. Devasia et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Incidence of Moxifloxacin Resistance in Clinical Mycobacterium tuberculosis Isolates in Houston, Texas

(2011) H. M. El Sahly et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China

(2011) Yi Hu et al.   TUBERCULOSIS

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes

(2011) Jinwoo Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

(2010) Armand Van Deun et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Molecular Characterization of Fluoroquinolone Resistance inMycobacterium tuberculosis: Functional Analysis ofgyrAMutation at Position 74

(2010) Ricky W. T. Lau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model

(2010) J. Poissy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex Isolates

(2010) J. van Ingen et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase

(2010) Jérémie Piton et al.   PLoS One

Beijing Genotype of Mycobacterium tuberculosis Is Significantly Associated with High-Level Fluoroquinolone Resistance in Vietnam

(2009) D. D. An et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China

(2009) P. Xu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB

(2009) A. Von Groll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutagenesis in the  3 4 GyrA Helix and in the Toprim Domain of GyrB Refines the Contribution of Mycobacterium tuberculosis DNA Gyrase to Intrinsic Resistance to Quinolones

(2008) S. Matrat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Characterization of Ofloxacin-Resistant Mycobacterium tuberculosis Strains from Russia

(2008) I. Mokrousov et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY